GlobeNewsWire
10 Jul 2026, 01:40 UTC · 18w ago
Cue Biopharma Announces $50.0 Million Private Placement
Impact · against what's priced in
Cue Biopharma has significantly strengthened its balance sheet and validated its scientific approach through a $50 million private placement led by top-tier biotech investors. The confirmation of a Phase 2 data readout by Q3 2026 provides a clear near-term catalyst for the stock.
- CUE+0.60
No priced-in read yet
- In context
The $50 million capital raise led by Cormorant Asset Management reduces liquidity risk and provides a validated runway. Additionally, the specific timeline for Phase 2 CSU study data by the end of Q3 2026 creates a concrete catalyst for price action.
Read from the article alone

- healthcare
- CUE
- biopharma
- biotechnology
- capital raise
- clinical stage
- immunological disorders
- private placement
Search tags




